The estimated Net Worth of Venture Partners Lp Longitu... is at least $17.8 Milión dollars as of 15 November 2016. Venture Longitu owns over 174,847 units of Corcept Therapeutics Inc stock worth over $6,808,607 and over the last 16 years Venture sold CORT stock worth over $11,033,323.
Venture has made over 8 trades of the Corcept Therapeutics Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently Venture sold 174,847 units of CORT stock worth $1,669,789 on 15 November 2016.
The largest trade Venture's ever made was buying 4,642,857 units of Corcept Therapeutics Inc stock on 6 February 2009 worth over $3,203,571. On average, Venture trades about 895,909 units every 258 days since 2009. As of 15 November 2016 Venture still owns at least 191,522 units of Corcept Therapeutics Inc stock.
You can see the complete history of Venture Longitu stock trades at the bottom of the page.
Over the last 21 years, insiders at Corcept Therapeutics Inc have traded over $107,318,493 worth of Corcept Therapeutics Inc stock and bought 71,912,273 units worth $127,133,071 . The most active insiders traders include Patrick G Enright, Allen Andersson a Ventures, Llc Paperboy. On average, Corcept Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $8,010,233. The most recent stock trade was executed by William Guyer on 3 September 2024, trading 10,000 units of CORT stock currently worth $216,500.
leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis
Corcept Therapeutics Inc executives and other stock owners filed with the SEC include: